期刊文献+

TRAIL重组蛋白诱导肝癌细胞HepG2凋亡的研究 被引量:3

Apoptosis-inducing Effect of HrsTRAIL on Hepatoma Cell Line HepG2
原文传递
导出
摘要 目的研究重组人肿瘤坏死因子相关的凋亡诱导配体(TRAIL)蛋白诱导肝癌细胞HepG2的凋亡作用和意义。方法HepG2细胞经重组人可溶性TRAIL蛋白处理后,以MTT法测定细胞存活率、流式细胞术检测细胞凋亡指数。结果TRAIL蛋白对HepG2的作用存在较好的量效和时效关系,其最佳作用剂量和最佳作用时间分别为1 000 ng/ml和24h;1 000 ng/ml的TRAIL蛋白作用24 h后,HepG2肝癌细胞的存活率降至45%,凋亡指数达51%。结论TRAIL重组蛋白能通过诱导细胞凋亡的方式杀伤一定量的HepG2肝癌细胞,有可能成为潜在的抗肝癌新药。 Objective To study the apoptosis-inducing effect and its significance of human recombination soluble TRAIL (HrsTRAIL) on hepatoma cell line HepG2. Methods HepG2 cells were treated with HrsTRAIL and then the viability of HepG2 cells was measured by microcuhure tetrazolium dye (MTI') assay and apoptosis index was demonstrated by fluorescence-activated cell sorting (FACS). Results HrsTRAIL had potent antitumor activity in a time- and dose-dependent manner. After co-incu- bations of the HepG2 cells in the presence of HrsTRAIL at a concentration of 1 000 ng/ml for 24 hours, the viability of HepG2 cells decreased to 45% and the apoptosis index reached to 51%. Conclusion HrsTRAIL can kill HepG2 cells by inducing apoptosis, so HrsTRAIL might be a potential new cytotoxic drug for PHC.
出处 《苏州大学学报(医学版)》 CAS 北大核心 2009年第6期1072-1075,共4页 Suzhou University Journal of Medical Science
关键词 肿瘤坏死因子相关的凋亡诱导配体 人重组蛋白 肝癌 凋亡 TRAIL human recombination protein hepatoma apoptosis
  • 相关文献

参考文献9

  • 1Pan G, Ni J, Wei YF, et al. An antagonist decoy receptor and a death domain-containing receptor for TRAIL [ J ]. Science, 1997,277 ( 5327 ) : 815 - 818.
  • 2Lacour S, Hammann A, Wotawa A, et al. Anticancer agents sensitize tumor cells to tumor necrosis factor-related apoptosis-inducing ligand-mediated caspase-8 activation and apoptosis [ J ]. Cancer Res, 2001,61 (4) : 1645 - 1651.
  • 3Pan G, Rorke K, Chinnaiyan AM, et al. The receptor for the cytotoxic ligand TRAIL [J]. Science, 1997, 276 (5309) :111 - 113.
  • 4Shivapurkar N, Toyooka S, Toyooka KO, et al. Aberrant methylation of trail decoy receptor genes is frequent in multiple tumor types [J]. Int J Cancer, 2004,109(5): 786 -92.
  • 5Satoh K, Kaneko K, Hirota M, et al. Tumor necrosis factor-related apoptosis-inducing ligand and its receptor expression and the pathway of apoptosis in human pancreatic cancer [ J ]. Pancreas,2001,23 ( 3 ) :251 - 258.
  • 6Guan B, Yue P, Lotan R, et al. Evidence that the human death receptor 4 is regulated by activator protein 1 [ J ]. Oncogene,2002,21 (20) :3121 - 3129.
  • 7Arts HJ, De Jong S, Hollema H, et al. Chemotherapy induces death receptor 5 in epithelial ovarian carcinoma [ J ]. Gynecol Oncol, 2004,92 (3) :794 - 800.
  • 8Lin Y, Liu X, Yue P, et al. Involvement of c-FLIP and survivin down-regulation in flexible heteroarotinoid-induced apoptosis and enhancement of TRAIL-initiated apoptosis in lung cancer cells [ J ]. Mol Cancer Ther, 2008, 7 ( 11 ) : 3556 - 3565.
  • 9Klener P Jr, Leahomschi S, Molinsky J, et al. TRAIL-induced apoptosis of HL60 leukemia cells: two distinct phenotypes of acquired TRAIL resistance that are accompanied with resistance to TNFalpha but not to idarubicin and cytarabine [ J ]. Blood Cells Mol Dis, 2009, 42 ( 1 ) :77 - 84.

同被引文献34

引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部